Business Context and Reporting Period
This Form 8-K Current Report was filed by Pieris Pharmaceuticals, Inc. on August 27, 2015. The filing discloses two material events: the execution of a sublease agreement for new corporate headquarters in Boston, Massachusetts, and the appointment of a new Chief Financial Officer effective September 1, 2015.
Key Financial Metrics and Agreements
The filing does not provide revenue, profit, cash flow, or margin data. Key financial terms disclosed relate to operational commitments:
- Lease Commitment: The Company will pay an average of approximately $195,525 annually in rent, commencing two months after the lease start date.
- Executive Compensation: The new CFO will receive a base salary of $300,000 and is eligible for an annual discretionary bonus of up to 40% of base salary.
- Equity Grant: The new CFO received an option to purchase 450,000 shares of common stock, vesting over four years.
Material Changes
The filing reports the following material changes:
- Corporate Relocation: The Company entered into a sublease for approximately 3,950 square feet at 255 State Street, Boston, to serve as its new corporate headquarters. The term runs from the commencement date until February 27, 2022.
- Executive Leadership: Darlene Deptula-Hicks was promoted from Acting Chief Financial Officer to Chief Financial Officer and Senior Vice President.
Outlook, Risks, and Contingencies
Lease Contingencies: The sublease is subject to termination if the Company fails to remedy breaches, becomes insolvent, or if the master lease between the landlord and sublandlord terminates. The Company may terminate the agreement if landlord consent is not obtained within 45 days, renovations are not complete within 90 days, or the premises are destroyed.
Employment Termination Provisions: The CFO's employment agreement includes severance provisions. In the event of termination without cause or for good reason, the executive is entitled to 12 months of salary plus a pro-rated target bonus and 12 months of COBRA coverage. Equity awards vest immediately upon such termination (50% of unvested awards in non-change-of-control scenarios; 100% in change-of-control scenarios).
Equity Plan Risk: The stock option granted to the CFO is contingent upon shareholder approval of an increase in authorized shares under the 2014 Equity Incentive Plan by September 30, 2016. If approval is not obtained, the option will be cancelled.
Investor Verification Checklist
- Verify the exact "Commencement Date" of the Boston lease once renovations are complete.
- Confirm whether shareholder approval for the equity plan increase is obtained by September 30, 2016, to validate the CFO's stock option.
- Review the full Sublease Agreement and Employment Agreement when filed as exhibits to subsequent periodic reports for complete legal terms.
- Monitor the Company's cash position to ensure it can support the new annual rent obligation of approximately $195,525.